<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069416</url>
  </required_header>
  <id_info>
    <org_study_id>68954200</org_study_id>
    <nct_id>NCT04069416</nct_id>
  </id_info>
  <brief_title>Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Criteria</brief_title>
  <official_title>Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Criteria in High Prevalence Young HCC Patients Country.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to evaluate the impact of expanding criteria beyond Milan on tumor
      recurrence and patient survival that will help identify the best selection criteria for HCC
      transplanted patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:

      HEPATOCELLULAR CARCINOMA (HCC) is the second leading cause of cancer mortality worldwide.
      Living donor liver transplantation (LDLT) for HCC patients has emerged as a rewarding therapy
      for a cure and a successful alternative where a Deceased donor liver transplantation (DDLT)
      program is lacking. Therefore, trials for careful expansion to Milan criteria have been
      adopted.

      Aim of the study:

      To evaluate the impact of expanding criteria beyond Milan on tumor recurrence and patient
      survival that will help identify the best selection criteria for HCC transplanted patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2004</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HCC recurrence</measure>
    <time_frame>3 years</time_frame>
    <description>Recurrence of Hepatocellular carcinoma either intra-hepatic, extra-hepatic or both</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">241</enrollment>
  <condition>Hcc</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <description>175 patients who fall within the Milan criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <description>36 patients who fall within up-to-7 criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <description>30 patients beyond up-to-7 criteria and will be termed beyond all criteria (BAC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>living donor liver transplantation</intervention_name>
    <description>liver graft from a living donor</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients were divided according to the pre-transplant radiological findings of HCC nodules
        number and sizes into 3 groups:

        Group I: comprised 175 patients who fall within the Milan criteria. Group II: included 36
        patients who fall within up-to-7 criteria (the sum of the number of the tumors and diameter
        of the largest tumor not exceeding 7cm) Group III: included 30 patients beyond up-to-7
        criteria and will be termed beyond all criteria (BAC).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patient transplanted for HCC eligible for transplant (no vascular invasion-no
             extra hepatic metastasis)

          -  age&gt;18y

        Exclusion Criteria:

          -  other etiology for liver transplant rather than HCC

          -  patient not fit for surgery

          -  age &gt;70y
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Manar Salah</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>liver transplant</keyword>
  <keyword>HCC</keyword>
  <keyword>Extended milan</keyword>
  <keyword>Living donor liver transplantation</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

